Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18274730 | 0.83 | KDM4E (0.34) | KDM4ELMNA | |
| SCHEMBL12559796 | 0.83 | GAA (0.34) | TDP1KDM4ELMNA | |
| SCHEMBL4593017 | 0.82 | LMNA (0.39) | ALDH1A1TSHRTDP1HTR2CTLR8 | |
| SCHEMBL19822063 | 0.82 | CYP1A2 (0.38) | ALDH1A1TSHRTDP1CYP1A2 | |
| SCHEMBL28098710 | 0.81 | KDM4E (0.31) | TDP1KDM4ELMNA | |
| SCHEMBL28806657 | 0.81 | CYP1A2 (0.33) | HTR2CKDM4ELMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL3067297 | 0.80 | CYP1A2 (0.36) | ALDH1A1TSHRTDP1KDM4ELMNA | |
| SCHEMBL12559721 | 0.80 | NAAA (0.32) | ALDH1A1HTR2CTLR8TLR7LMNA | |
| SCHEMBL2380925 | 0.80 | ALDH1A1 (0.39) | ALDH1A1TSHRTDP1CYP1A2 | |
| SCHEMBL142215 | 0.80 | TSHR (0.39) | ALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0141269-B1 | MODIFIED POLYVINYL ALCOHOL POLYMERS | ICI AMERICAS INC. (US) | 1989-08-23 | — | — | EP | claimed |
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| WO-2023178299-A1 | PRODRUGS OF GANAXOLONE | MARINUS PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| CN-106061942-B | Novel CYP-eicosanoid derivatives | 分子医学马克斯德尔布吕克中心 | 2019-11-15 | — | — | CN | disclosed |
| CN-110072883-A | The relevant peptide of therapeutic MOTS-C | 科巴公司 | 2019-07-30 | — | — | CN | disclosed |
| EP-3492526-A1 | RESIN COMPOSITION AND USE THEREOF | Sumitomo Chemical Company Limited (JP) | 2019-06-05 | — | — | EP | disclosed |
| CN-109574865-A | Monoamine oxidase-B selective depression immunomodulator compounds, its pharmaceutical composition and application | 英属哥伦比亚大学 | 2019-04-05 | — | — | CN | disclosed |
| CN-109562083-A | CYP-eicosanoid analogs for treatment or prevention of diseases associated with neovascularization and/or inflammation | 奥迈科斯治疗公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109414475-A | New type of peptides and peptide mimics | 奥克兰大学 | 2019-03-01 | — | — | CN | disclosed |
| CN-105793234-B | Monoamine oxidase-B selective inhibitor compound, pharmaceutical composition and application thereof | 英属哥伦比亚大学 | 2018-10-12 | — | — | CN | disclosed |
| CN-108349880-A | The steady analog of CYP eicosanoid metabolics for treating heart disease | 奥迈科斯治疗公司 | 2018-07-31 | — | — | CN | disclosed |
| CN-105007990-B | The purposes of cosmetic composition from fish artemia hatching solution, its production method and its aesthetic appearance for being used to improving skin | 阿克生物科技公司 | 2018-04-06 | — | — | CN | disclosed |
| CN-106999534-A | Composition and method for treating acute radiation syndrome | 倍奥英赛普特有限责任公司 | 2017-08-01 | — | — | CN | disclosed |
| CN-105793234-A | Monoamine oxidase-B selective inhibitor compound, pharmaceutical composition and application thereof | 英属哥伦比亚大学 | 2016-07-20 | — | — | CN | disclosed |
| US-8778919-B2 | Cyclic anilino—pyridinotriazines | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-15 | — | — | US | disclosed |
| US-20100222574-A1 | CYCLIC ANILINO - PYRIDINOTRIAZINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-02 | — | — | US | disclosed |
| EP-1904461-B1 | CYCLIC ANILINO-PYRIDINOTRIAZINES AS GSK-3 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-12 | — | — | EP | disclosed |
| CN-1330712-A | Biogical compositions, components thereof and uses therefor | MELBOURNE HEALCH CARE LTD (AU) | 2002-01-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | ALDH1A1 3305/4885TSHR 140/4885TDP1 3206/4885 |
| US-20100222574-A1 | CYCLIC ANILINO - PYRIDINOTRIAZINES | NR4A1, NR4A2, NR5A2 | ALDH1A1 2052/4885TSHR 767/4885TDP1 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.